BigAlMoney
:
Before end of May we will have partner for Fabry, expecting 300-400 million up front and biobucks, should be interesting since our current market cap is around 160 mill
$Sangamo Therapeutics (SGMO.US)$ This licensing agreement materially strengthens Sangamo's financial position through a $18 million upfront payment that significantly bolsters their balance sheet. For context, this single payment represents approximately 14% of Sangamo's entire market capitalization ($128.6 million), making it an exceptionally material transaction. The deal's structure is particularly advantageous for Sangamo, as it creates asymmetric upside with minimal ongoin...
$Sangamo Therapeutics (SGMO.US)$ Sangamo's licensing deal with Eli Lilly represents a significant value-creation event for the company. The $18 million upfront payment is substantial for Sangamo, representing approximately 14% of their $128.6 million market capitalization. This non-dilutive funding provides immediate capital without shareholder dilution. The agreement's structure is particularly favorable - Sangamo transfers technology but bears no further development c...
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Sangamo Therapeutics Stock Discussion
This licensing agreement materially strengthens Sangamo's financial position through a $18 million upfront payment that significantly bolsters their balance sheet. For context, this single payment represents approximately 14% of Sangamo's entire market capitalization ($128.6 million), making it an exceptionally material transaction.
The deal's structure is particularly advantageous for Sangamo, as it creates asymmetric upside with minimal ongoin...
Sangamo's licensing deal with Eli Lilly represents a significant value-creation event for the company. The $18 million upfront payment is substantial for Sangamo, representing approximately 14% of their $128.6 million market capitalization. This non-dilutive funding provides immediate capital without shareholder dilution.
The agreement's structure is particularly favorable - Sangamo transfers technology but bears no further development c...
👀
No comment yet